Elicio Therapeutics Insider Trades
NASDAQ: ELTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Last 12 months
- Purchases
- 0 · $0
- Sales
- 0 · $0
- Shares bought / sold
- 0 / 0
- Net activity
- Net buying $0
Elicio Therapeutics insider activity
Over the last 12 months, Elicio Therapeutics insiders reported 5 transactions on SEC Form 4: 0 open-market purchases and 0 sales. The most recent filing shows Shah Preetam (See Remarks) reporting a transaction in 24,000 shares on Feb 2, 2026. Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put ELTX's ownership changes in context.
Summary generated from market data by MetaCap's automated system. Methodology
ELTX insider transactions
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Feb 2, 2026 | Connelly RobertCEO, President and Director | Award | 73,600 | — | Form 4 |
| Feb 2, 2026 | Haqq ChristopherSee Remarks | Award | 25,400 | — | Form 4 |
| Feb 2, 2026 | DeMuth PeterChief Scientific Officer | Award | 20,800 | — | Form 4 |
| Feb 2, 2026 | Shah PreetamSee Remarks | Award | 24,000 | — | Form 4 |
| Dec 9, 2025 | DeMuth PeterChief Scientific Officer | Option exercise | 362 | $1.60K | Form 4 |
| Mar 5, 2025 | Chudnovsky Yekaterina & GKCC, LLCDirector | Conversion | 3,500,573 | $20.34M | Form 4 |
| Dec 16, 2024 | DeMuth PeterChief Scientific Officer | Option exercise | 381 | $1.68K | Form 4 |
| Nov 26, 2024 | Venkatesan JayDirector | Option exercise | 50,000 | $500 | Form 4 |
Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4